We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA 将 Vyvgart 适应症扩展至所有全身型重症肌无力患者。了解这将如何改变治疗市场。阅读分析。
